FLT3 and neoplasm: Among all the 12 signature genes in the risk score model, we found that most of the genes were statistically different between tumor tissues and normal controls, and in particular, two genes (PPARGC1A and FLT3) were decreased in the tumor tissue (Fig. 4C).